Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-15-000064
Filing Date
2015-11-12
Accepted
2015-11-12 08:55:02
Documents
11
Period of Report
2015-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q c617-20150930x10q.htm 10-Q 979791
2 EX-31.1 c617-20150930xex311.htm EX-31.1 14676
3 EX-31.2 c617-20150930xex312.htm EX-31.2 14595
4 EX-32.1 c617-20150930xex321.htm EX-32.1 11827
5 GRAPHIC c617-20150930x10qg001.jpg GRAPHIC 18865
  Complete submission text file 0000926617-15-000064.txt   2409506

Data Files

Seq Description Document Type Size
6 EX-101.INS c617-20150930.xml EX-101.INS 242257
7 EX-101.SCH c617-20150930.xsd EX-101.SCH 19790
8 EX-101.CAL c617-20150930_cal.xml EX-101.CAL 29823
9 EX-101.DEF c617-20150930_def.xml EX-101.DEF 53585
10 EX-101.LAB c617-20150930_lab.xml EX-101.LAB 172270
11 EX-101.PRE c617-20150930_pre.xml EX-101.PRE 131029
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
VERMILLION, INC. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 151221763
SIC: 2835 In Vitro & In Vivo Diagnostic Substances